Targeted therapy for triple-negative breast cancer: where are we?

International Journal of Cancer. Journal International Du Cancer
M J DuffyJ Crown

Abstract

Breast cancers that are negative for estrogen receptor (ER), progesterone receptors (PR) and HER2, using standard clinical assays, have been dubbed triple-negative (TN). Unlike other molecular subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer. Preclinical studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2). Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer. The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.

References

Aug 30, 2000·Nature·C M PerouD Botstein
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Román Pérez-SolerPhilip Bonomi
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenCharles M Perou
Jan 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ki Young ChungLeonard B Saltz
Dec 6, 2006·Cancer·Emad A RakhaIan O Ellis
Mar 28, 2007·Clinical Breast Cancer·Robert O Dillman, Stephanie E McClure
Aug 1, 2007·BMC Genomics·Katherine A HoadleyCharles M Perou
Oct 18, 2007·British Journal of Cancer·M FrattiniL Mazzucchelli
Dec 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles A ButtsFrances A Shepherd
Nov 26, 2008·Breast Cancer Research : BCR·Connie W LeeDario C Altieri
Dec 17, 2008·Cancer Research·Alan Ashworth
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabrice AndreLajos Pusztai
Jan 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B CorkeryN O'Donovan
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emad A RakhaIan O Ellis
Apr 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fotios LoupakisAlfredo Falcone
May 16, 2009·Current Cancer Drug Targets·B C BrowneN O'Donovan
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Jul 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Klaus P HoeflichMark R Lackner
Jul 2, 2009·Proceedings of the National Academy of Sciences of the United States of America·Carrie R GraveelGeorge F Vande Woude
Jul 21, 2009·Proceedings of the National Academy of Sciences of the United States of America·Marisa G PonzoMorag Park
Sep 30, 2009·Nature Reviews. Clinical Oncology·Lori C KimEric B Haura
Dec 22, 2009·American Journal of Clinical Oncology·Anthony D Elias
Dec 25, 2009·Trends in Molecular Medicine·Xiangdong LiuPeggy A Scherle
Jan 6, 2010·EMBO Molecular Medicine·Ana M Mendes-PereiraAlan Ashworth
Jan 23, 2010·Breast Cancer Research and Treatment·Edith A PerezCathy A Andorfer
Jan 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lihua H WangRobert J Kinders
Mar 5, 2010·Nature Reviews. Cancer·Michèle RouleauGuy G Poirier
Mar 23, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fabiola CecchiDonald P Bottaro
Apr 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Asima MukhopadhyayNicola J Curtin
Apr 14, 2010·Cancer Treatment Reviews·Eitan AmirAlberto Ocana
Apr 29, 2010·Molecular Cancer Therapeutics·Stacy MoulderLajos Pusztai
May 13, 2010·Breast Cancer Research : BCR·Bryan P Rowe, Peter M Glazer

❮ Previous
Next ❯

Citations

May 16, 2014·Nanomedicine·Rajaletchumy Veloo KuttySi-Shen Feng
Aug 3, 2014·Expert Opinion on Therapeutic Targets·Patricia B GauleMichael J Duffy
Sep 5, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Luigi SapioSilvio Naviglio
Dec 18, 2013·Expert Opinion on Drug Discovery·Matthew D Breyer
Jun 4, 2013·Seminars in Nuclear Medicine·Lale Kostakoglu
Oct 13, 2015·European Journal of Medicinal Chemistry·Chih-Wei FuWen-Shan Li
Feb 26, 2013·Proteomics. Clinical Applications·Angelo Gámez-PozoJuan Ángel Fresno Vara
Oct 22, 2013·Histopathology·Gillian O'HurleyWilliam M Gallagher
Aug 19, 2015·British Journal of Cancer·Maeve MulloolyMichael J Duffy
Apr 19, 2016·Biochemical and Biophysical Research Communications·Yong Yang
Apr 15, 2015·Endocrine-related Cancer·Juan Díaz-MartínJosé Palacios
Sep 26, 2013·The Breast : Official Journal of the European Society of Mastology·Roxana ChioreanIoana Berindan-Neagoe
Dec 3, 2014·Biochemical and Biophysical Research Communications·Feng Wang, Yong Yang
Mar 5, 2016·Endocrine-related Cancer·Francesco CaiazzaMichael J Duffy
Apr 14, 2016·International Journal of Cancer. Journal International Du Cancer·Annette LashamCristin G Print
Sep 13, 2016·International Journal of Cancer. Journal International Du Cancer·N C SynnottM J Duffy
May 16, 2019·Clinical and Experimental Pharmacology & Physiology·Pingping LiPeijun Liu
Aug 21, 2013·The Oncologist·François BertucciDaniel Birnbaum
Mar 23, 2018·Breast Cancer Research and Treatment·Michael J DuffyJohn Crown
Apr 12, 2020·Cancers·Elena VagiaMassimo Cristofanilli
Apr 27, 2018·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Gamze Guney EskilerBerrin Tunca
May 18, 2021·Chemistry & Biodiversity·Han ChenXiaoling Lu
Dec 26, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Silvia SaueressigFabiana Kömmling Seixas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Lisa A CareyEric Winer
Annals of Oncology : Official Journal of the European Society for Medical Oncology
P M McGowanM J Duffy
The New England Journal of Medicine
William D FoulkesJorge S Reis-Filho
Therapeutic Advances in Medical Oncology
Monica ArnedosFabrice André
Annals of Oncology : Official Journal of the European Society for Medical Oncology
K GelmonS Verma
© 2021 Meta ULC. All rights reserved